MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that its Chairman, CEO, and Co-founder, Dr. Shankar Musunuri, will deliver a key presentation at the 2025 Cell & Gene Meeting on the Mediterranean, taking place from April 15-17, 2025, in Rome, Italy. This prominent event gathers global leaders in advanced therapy medicinal products (ATMPs) to discuss innovations and strategies in the field.
Dr. Musunuri will join an expert panel titled “Commercializing ATMPs: Moving from Innovation to Market Success”, scheduled for Tuesday, April 15, 2025, from 10:45-11:30 a.m. CEST in the Salone dei Cavalieri. The discussion will focus on the critical challenges and approaches to bringing groundbreaking therapies to market while ensuring broad patient access.
Highlighting Ocugen’s contributions to the ATMP landscape, Dr. Musunuri plans to share insights on the company’s modifier gene therapy platform, which aims to revolutionize treatment options for major blindness diseases. He emphasized, “I look forward to sharing how Ocugen’s platform has the potential to offer a one-time treatment for life, fundamentally changing the treatment paradigm for blindness diseases impacting millions of patients worldwide.”
Ocugen’s innovative gene therapies, including OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, have all received ATMP classifications from the European Medicines Agency’s Committee for Advanced Therapies. These designations underscore the therapies’ potential as cutting-edge solutions for patients with significant unmet medical needs.
Beyond the panel discussion, Dr. Musunuri will hold one-on-one meetings with stakeholders to highlight Ocugen’s business and clinical development strategies. The event will also offer hybrid participation, with virtual attendees able to stream panels, workshops, and presentations.
The Cell & Gene Meeting on the Mediterranean, organized by the Alliance for Regenerative Medicine, serves as a pivotal platform to address commercialization, regulatory, and market access challenges within the ATMP community. Ocugen’s active participation reinforces its commitment to advancing regenerative medicine and delivering transformative therapies to patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.